| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc. | 10%+ Owner | Common Stock | 1.23M | $55.5M | $45.29 | Nov 29, 2022 | Indirect |
| Eloxx Pharmaceuticals, Inc. | 10%+ Owner | Common Stock | 617K | $444K | $0.72 | May 13, 2021 | By Pontifax Investment Fund |
| LB PHARMACEUTICALS INC | 10%+ Owner | Common Stock | 1.41M | Sep 12, 2025 | Indirect | ||
| Keros Therapeutics, Inc. | 10%+ Owner | Call Options (obligation to sell) | 0 | Nov 29, 2022 | Indirect | ||
| LB PHARMACEUTICALS INC | 10%+ Owner | Series C Preferred Stock | 0 | Sep 12, 2025 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | Sep 12, 2025 | 3 | $15M | 4 | Sep 16, 2025 | 10%+ Owner |
| LBRX | LB PHARMACEUTICALS INC | Sep 10, 2025 | 0 | $0 | 3 | Sep 11, 2025 | 10%+ Owner |
| KROS | Keros Therapeutics, Inc. | Nov 29, 2022 | 6 | -$1 | 4 | Nov 30, 2022 | 10%+ Owner |
| ELOX | Eloxx Pharmaceuticals, Inc. | May 13, 2021 | 4 | $8M | 4 | May 17, 2021 | 10%+ Owner |
| KROS | Keros Therapeutics, Inc. | Apr 7, 2020 | 0 | $0 | 3/A | Nov 30, 2022 | 10%+ Owner |